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Background: Carrageenans are naturally occurring hydrophilic, polyanionic polysaccharide bioploymers with
wide application in pharmaceutical industries for controlled drug delivery. Magnetic nanoparticles with their
exceptional properties enable them to be an ideal candidate for the production of functional nanostructures,
thus facilitating them for biomedical applications. The development of novel nanocomposite by coupling the
synergistic effects of the sulfated polysaccharide (iota carrageenan) and a magnetic nanoparticle (maghemite)
may offer new interesting applications in drug delivery and cancer therapy. The nanocomposite was characterized by
ultraviolet–visible spectroscopy, high resolution scanning electron microscopy, dynamic light scattering analysis,
Fourier transform infrared spectroscopy and powder XRD to highlight the possible interaction between the two
components. Biocompatibility and the anticancer efficacy of the nanocomposite were assayed and analysed
in vitro.
Results: Results suggested that iota carrageenans have electrostatically entrapped the maghemite nanoparticles
in their sulfate groups. Biocompatibility of the nanocomposite (at different concentrations) against normal cell
lines (HEK-293 and L6) was confirmed by MTT assay. Hoechst 33342 and 7-AAD staining studies under fluorescent
microscopy revealed that the nanocomposite is able to induce appoptosis as the mode of cell death in human
colon cancer cell line (HCT116). Cell apoptosis here is induced by following the ROS-mediated mitochondrial
pathway, combined with downregulation of the expression levels of mRNA of XIAP and PARP-1 and upregulation
of caspase3, Bcl-2 and Bcl-xL.
Conclusions: This novel nanocomposite is biocompatible with potential properties to serve in magnet aided
targeted drug delivery and cancer therapy.
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HyperthermiaIntroduction
The advancements in the area of nanoparticles and
nanotechnology have offered an understanding and
management of the materials at atomic and molecular
levels. It has also assisted in fabricating advanced mate-
rials with added magnetic, electrical, optical and* Correspondence: mukeshd@iitm.ac.in
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applications [1]. Nanovectors in the field of delivery are
promising novel tools for controlled release of drugs. In
recent years, the unique novel properties (superparamag-
netism, high coercivity, low Curie temperature and high
magnetic susceptibility) of iron oxide nanoparticles (mag-
netite, maghemite) have been exploited to make it inevit-
able in magnetic resonance imaging (MRI), magnetic fluid
hyperthermia, controlled drug delivery systems and cancer
therapy [2]. Nevertheless, these magnetic nanoparticlesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 SEM micreograph (A) carrageenan with no nanoparticles
(B) carrageenan with maghemite nanoparticles forming ι-car-γ-
Fe2O3 nanocomposite.
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incorporated with suitable polymer [3,4]. Encapsulating
magnetic nanoparticles within a polymer not only stabi-
lizes the nanoparticles but also provides various chemical
functionalizations. Many polysaccharide-based magnetic
nanocomposites such as, magnetite (Fe3O4)-dextran,
Fe3O4-chitosan, Fe3O4-alginate, Fe3O4-heparin, Fe3O4-
pullulan acetate, Fe3O4-starch, Fe3O4-κ-carrageenan,
maghemite (γ-Fe2O3)-dextan/sucrose, were successfully
used in bioseparation and purification [5,6], bioassays and
sensors [7-9], biolabelling and imaging [10,11], cancer
hyperthermia [12,13], cardiovascular therapies [14] and
drug delivery [15,16].
Carrageenans are naturally occurring high molecular
weight, hydrophilic polysaccharides extracted from red sea
weeds of phylum Rhodophyta. These are polyanionic linear
sulfated galactans with a sequence of D-galactopyranose
and 3,6-anhydrogalactopyranose residues bonded by alter-
nating α(1→3) and β(1→4) linkages [17]. Based on the
number and position of ester sulfate groups (−SO3
−) on the
galactose units, these are classified into kappa (κ) -, iota
(ι) -, and lambda (λ) – carrageenan (main commercial vari-
ants). ι –Carrageenan (ι –car) is composed of D-galactose-
4-sulphate (G4S) and 3, 6-anhydro-D-galactose-2-sulfate
(DA2S). These biocompatible and biodegradable bioma-
cromolecules are extensively used in food and pharmaceut-
ical industries. In pharmaceutical industry, these play a
significant role as gelling agents in controlled drug release
and prolonged retention. Their anticancer, antioxidant,
anticoagulant, antihyperlipid, antiviral and immunomodu-
latory activities have gained several pharmacological appli-
cations [18,19]. The ι-carrageenan has been reported to
possess high metal binding activity [20]. They are reported
to act as sorbents and aid in binding heavy metals includ-
ing yttrium (Y3+) and lead ions (Pb2+) [20]. This intrinsic
metal binding property of carrageenans and other polysac-
charides are successfully employed in nanoparticle synthe-
sis and encapsulation; and hence, in making nanoparticles
suitable for a broad spectrum of biomedical and biotech-
nological applications [21].
Carneiro et al. [22] reported that γ- Fe2O3 nanoparticles
coated citrate and rhodium (II) citrate enhance cytotox-
icity on breast carcinoma. Degraded ι – car was also re-
ported to have antitumor activity towards human
osteosarcoma cell line both in vitro and in vivo [23].
Hence, the synergic effect of the nanoparticles and the
polysaccharides could be a new area of research which
could confer beneficial functionalities and multiple bio-
applications to the product developed. In our study,
γ – maghemite (Fe2O3) nanoparticles were combined with
ι – car in a significant way to develop a novel nanocom-
posite material. These were then characterized and sub-
jected to in vitro studies to open up their possible range of
applications in cancer research.Results and discussion
ι-car is an anionic polysaccharide with high ζ-
potential value. This anionic nature is because of the
sulfate group in each unit of D-galactopyranose-4-sul-
fate and 3, 6-anhydrogalactose units. The ζ-potential of
ι-car was −52.84 ± 3.6 mV and that of ι-car-γ-Fe2O3
nanocomposite was −7.70 ± 2.8 mV. This lowering in
surface charge of the latter could be attributed to the in-
clusion of the positively charged γ- Fe2O3 nanoparticles
(+33 ± 3 mV) to the surface of anionic ι-car. The electro-
static attraction between anionic sulfate groups (−SO−4) on
the carrageenan molecule and cationic patches (−Fe2+) on
maghemite may interact and contribute to the nanocom-
posite size and zeta potential [24]. Similar results were re-
ported in many studies and this change in the ζ-potential
could be highly dependent on the concentration of com-
ponents in the composite [25,26]. SEM micrographs
showed maghemite nanoparticles dispersed throughout
the carrageenan microfibrils (Figure 1). However, for in
vitro studies, the nanoparticle dispersed microfibrillar
composite was ultrasonicated and washed in buffer to get
nanometer sized particles that were larger than maghe-
mite nanoparticles (21 ± 3.6 nm) used in the preparation
of the composite. The average particle size ranging from
200 – 550 ± 10 nm was observed and this wide range of
distribution may be due to their aggregation (Additional
file 1).
The UV absorption maxima for ι-car was observed at
296 nm, which shifted to 304 nm in the nanocomposite
possibly indicating structural modification in ι-car, which
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ticles [27] (Additional file 2).
The FTIR bands specific to ι-car are observed in both
the samples (Figure 2, Table 1), with few exceptions in
the lower fingerprint region (800–400 cm−1). Broad
bands are observed between 3400–3000 cm−1 corre-
sponding to the hydroxyl groups in the polysaccharide
which is responsible for the hydrophilic nature of the
carrageenan [28]. The bands between 2900–2700 cm−1
are assigned to the asymmetrical stretching vibrationsFigure 2 FTIR spectrum of (A) ι-car and ι-car-γ-Fe2O3 nanocomposite
and ι-car-γ-Fe2O3 nanocomposite.in -CH2 of the galactose units [28]. The characteristic
band in the 1210–1260 cm−1 region was attributed to
the sulfate esters that were present in both, confirming
the retention of the sulfation in the latter [29]. The peak
at 1070 cm−1 is attributed to glycosidic linkages in the
polysaccharides [29]. Presence of 3, 6-anhydro-D-galac-
topyranose units in both was confirmed from the
presence of bands at 894 and 917 cm−1, and that of D-
galactopyranose-4-sulfate (G4S) units by the presence of
bands at 848 and 846 cm−1. The band specific to ι-car(B) magnified lower finger print region of FTIR spectrum of ι-car
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fate group at C2-position in the 3, 6-anhydrogalactose
unit (DA2S) [30]. This band however shifts to lower
wavenumbers in the spectrum of the nanocomposite.
This as well as the shift observed at 917 cm−1 in the
nanocomposite may be due to the interaction of maghe-
mite nanoparticles with the sulfate ester group in the 3,
6- anhydrogalactose-2-sulfate units. The appearance of
sharp intense peak at 417 cm−1 corresponds to Fe-O
stretch (Figure 2B) [31]. This could possibly be due to
the impregnation of iron nanoparticles in ι-car mostly by
electrostatic interaction with the sulfate groups of 3, 6-
anhydrogalactose-2-sulfate units [27].
X-ray powder diffraction pattern of ι-car and ι-car-γ-
Fe2O3 nanocomposite indicate intense peaks at Bragg
angles (2θ), 28°and 40°, while less intense peaks at 36°,
50°, 11°, 29°, 20°, 66°, 17°, 23°, 46°, 18°, 41°, 45° and 58°.
γ-Fe2O3 nanoparticles have intense peaks at 35°, 63°, 57°
and 30°. The XRD-diffractogram of the nanocomposite
have the two intense peaks for ι-car (28° and 40°) and
two peaks specific for γ-Fe2O3 nanoparticles (66° and
58°) and other characteristic peaks of its own at 14°, 25°
and 26° (Figure 3, Table 2) [32,33]. Diffraction studies by
Millane et al. [32], Janaswamy and Chandrasekaran [33]
have shown that ι-car has a double helical structure
with sulfate protruding away from the centre of helix.
It has a trigonal lattice arrangement with small changes
in the unit cell dimensions when it interacts with the
nanoparticles.
Cell proliferation assay for ι-car (1000 μg/ ml) using 3-
[4, 5-dimethythiazol-2-yl]-3, 5-diphenyltetrazolium brom-
ide dye showed, 75.4% viability of HCT116 cells and no
cytotoxicity in HEK and L6 (more than 90% of viable
cells). Supportingly, Arrifin et al. [34], have observed that
iota carrageenan was non-cytotoxic to normal and cancer
intestinal and liver cell lines even at 2000 μg/ ml. MTT
assay with γ-Fe2O3 showed that the nanoparticles were
cytotoxic to HEK, L6 and HCT116 cell lines at 50 μg/ mland above (Additional file 3). This agrees with the studies
of Prodan et al. [35], which have demonstrated that γ-
Fe2O3 nanoparticles upto 30 μg/ ml concentration are
non-cytotoxic on HeLa cells. The ι-car-γ-Fe2O3 nanocom-
posite treatment induced dose-dependent death of HCT-
116 cells (reduction of cell viability from 98.8 to 68.4%
with an increase in the concentration from 50–500 μg/
mL, in 24 hours (p < 0.01)). The nanocomposite had no ef-
fects on the viability of HEK293 and L6 cell lines even at
the highest concentrations tested (Figure 4). The concen-
trations of ι-car (700 μg/ ml) and γ-Fe2O3 (4 μg/ ml) in
nanocomposite, when used independently had no effects
on the viability of HEK293 and L6 cell lines and hence
were biocompatible.
Nanocomposites comprising of maghemite have been
recognized for their anticancer properties [36,37] and ι-
car-γ-Fe2O3 nanocomposite is a novel compound that
could be a potent inducer of apoptosis in various cancer
cell lines. This could activate the extrinsic or intrinsic
apoptotic pathways by altering the expression of
apoptosis-associated or signaling proteins, cell cycle
regulatory proteins and transcription factors. However,
the molecular and cellular mechanism underlying these
effects in HCT116 has not yet been investigated till date.
The morphological changes in the HCT116 cells and
its nucleus, induced by apoptosis were examined with
different dyes. Apoptotic bodies (apoptosomes) were ob-
served with Hoechst 33342 staining in nanocomposite-
treated cells, but not in the control. These changes
might include chromatin condensation, membrane bleb-
bing and cell shrinkage. 7-AAD staining indicates com-
promised cellular membrane (late apoptotic and necrotic
cells), while live cells with intact cell membranes
remained dark (Figure 5A- C). Necrotic cell death might
not be significant [38]. Figure 5 (D, E) shows the results
of nanocomposite treated cells stained with acridine or-
ange and ethidium bromide for 24 h. Number of viable
cells here had decreased significantly. Apoptotic cells ap-
pear bright green or reddish with fragmented nuclei.
The decrease in green fluorescence observed in treated
cells when compared to control could be due to the re-
duction in the accessibility of nucleic acid by AO or re-
duced overall amount of DNA in the cells which
undergo apoptosis. Cells which undergo apoptosis are
permeable and, hence show increased fluorescence with
EB. Nanocomposite-treated cells showed a significant re-
duction in the cell numbers and about 82% of cells were
either orange or bright green apoptotic cells (apopto-
somes) with fragmented and condensed nuclei [39,40].
In the control, the cells were healthy with no fragmented
nuclei.
Annexin-V/PI double-staining and flow cytometry re-
vealed that the nanocomposite effectively induced apop-
tosis in HCT-116 cells. The proportion of apoptotic cells
Figure 3 Powder XRD diffractogram of (A) ι-car and (B) ι-car-γ-Fe2O3 nanocomposite.
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treated cells to 16.3% in nanocomposite-treated cells in
24 hours (Figure 6A). Compared to the ROS in the con-
trol, it is found that 1 mM of ascorbic acid markedly re-
duced the ROS level (59.7 ± 4.6% of control) in HCT116
cell lines. However, pre-incubation with ι-car-γ-Fe2O3
nanocomposite (500 μg/ ml) increased the ROS levels
significantly (80.8 ± 0.4% of control, p < 0.01).
ROS are the byproducts of normal cellular oxidative
process and are involved in the initiation of apoptotic
and inflammation signaling. Increased ROS levels induce
depolarization of the mitochondrial membrane which
produces an increased level of pro-apoptotic molecules
in the cells [41]. Oxidative stress indicates the imbalance
between pro-oxidants and anti-oxidants and this is con-
trolled by multiple factors, of which imbalances caused
by cellular damage is a critical one. ROS play a key role
in oxidative stress, and are generated as a by-product of
cellular metabolism, primarily in the mitochondria [42].
The accumulation of ROS may lead to various forms of
reversible and irreversible oxidative modifications to thecellular proteins, lipids and DNA, thus, accounting for
cellular damage [43]. Depending on the extent of oxida-
tive stress, elevated levels of ROS can induce prolifera-
tion, growth arrest, senescence and apoptosis [44].
In order to evaluate the effect of ι-car-γ-Fe2O3 nano-
composite on the increase in the hypodiploid cell pro-
portion, a cell cycle analysis was performed. Figure 6B
shows slight percentage increase in the number of cells
in the G2/M phase and decrease in the S-phase with re-
spect to the control. Percentage difference in the G0-
phase between the two is not statistically significant.
This defective G2/M phase in the nanocomposite treated
cells indicate that the entry of the cells into mitosis is
checked due to the DNA damage and hence, the cells
undergo apoptosis [45]. Cyclin regulatory proteins and
p53 pathway may have a significant role in the apoptosis
[46]. Nanocomposite is observed to induce accumulation
of cells in G1/S phase. Similar results are reported by
Haneji et al. for fucoidan-induced cell death [47]. They
also reported G1 arrest in human cancer cell, HCT116.
ι-car-γ-Fe2O3 nanocomposite leads to the downregulation
Table 2 Peak intensities of (A) ι-car and (B) ι-car- γ- Fe2O3
composite from PXRD diffractogram
(A) PXRD diffractogram
of ι-car
(B) PXRD diffractogram of
ι-car- γ- Fe2O3 composite
2θ d spacing (A°) I/100 2θ d spacing (A°) I/100
11.202 7.8924 24 14.507 6.1008 10
17.512 5.0602 16 20.517 4.3254 6
18.414 4.8144 14 23.221 3.8274 12
20.517 4.3253 20 28.33 3.1478 45
23.973 3.7091 16 31.034 2.8794 7
28.33 3.1478 100 32.837 2.7253 7
29.832 2.9926 23 38.696 2.325 6
36.743 2.444 27 40.499 2.2256 28
40.349 2.2335 75 50.265 1.8137 9
41.401 2.1792 14 58.528 1.5758 7
45.007 2.0126 13 66.341 1.4079 8
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and upregulation of caspase-3 [48]. Of the members of the
IAP protein family, XIAP, has been reported to exert the
strongest anti-apoptotic function, as it inhibits caspase-3
indicating that apoptosis is through the mitochondrial
pathway [49]. However, Bcl-2, Bcl-xL and caspase-3 are
upregulated in nanocomposite treated cells when com-
pared to the control (Figure 7). This indicates thatFigure 4 Cell proliferation assay: viability of various cells
(HEK293, L6 and HCT116) treated with ι-car, γ-Fe2O3 and ι-car-γ-
Fe2O3 nanocomposite. Significant difference (*, p < 0.01) is observed
between normal cell lines (HEK293 and L6) and HCT116. Concentration
dependent decrease in the viability is observed in HCT116 cell lines.the treatment leads to mitochondrial dysfunction in
HCT116 cells. PARP-1 (Poly (ADP-ribose) polymerase
1) is a nuclear enzyme that catalyzes the transfer of
ADP-ribose polymers onto itself and other nuclear pro-
teins in response to DNA strand break [50]. It has been
widely used as a hallmark of cell apoptosis that play an
important role in DNA replication and repair. Down-
regulation of PARP indicates the incapability of cells to
respond to DNA damage and hence induces apopotic
cell death [51].
Selective cleavage of 116 kD PARP between Asp214
and Gly215, to generate 89 and 24 kD polypeptides by
caspase-3 is a universal phenomenon. This is observed
during programmed cell death induced by an apoptotic
stimulus [52,53]. However, the Western blot of PARP
from nuclear extract of the ι-car-γ-Fe2O3 nanocomposite
treated and control HCT116 cells showed same band
density of uncleaved PARP (MW 116 kD) in the treated
cells (Additional file 4). No band appeared at 50 kD indi-
cating that the cell death did not involve necrosis [54,55].
The cell death in the treated cells with un-cleavable PARP
could be due to the activation of caspase-resistant PARP
and the subsequent depletion of intracellular NAD+ and
ATP [56,53]. Apoptotic cell death due to the augmented
levels of TNF-α and Fas were reported in fucoidan treated
HL-60 cells [57]. However, it was reported that cells with
PARP-null background (PARP−/−) exhibited a normal
apoptotic response to various stimuli including TNF-α
and anti-Fas treatment, suggesting that PARP is dis-
pensable in the apoptotic cascade [58,59]. This could be
understood possibly because PARP is not involved in
the apoptotic cell death caused by the nanocomposite
treated cells.
A20 is not significantly upregulated when compared to
the control in ι-car-γ- Fe2O3 nanocomposite treated
cells. It is a nuclear factor-κB (NF-κB) dependent gene
that shows both cell-type specific anti-apoptotic or pro-
apoptotic functions. Changes in the mRNA expression
levels of A20 could be related to both carcinogenesis
and inflammatory cell signalling [48]. NF-κB (nuclear
factor kappa-light-chain-enhancer of activated B cells) is
a eukaryotic transcription factor that contributes equally
to cell proliferation or cell death. Tumor necrosis factor-α
induced protein 3 (tnfaip3), a gene encoding A20 protein,
regulates NF-κB activation by interacting with various
components in the upstream signaling pathway. However,
both A20 and NF-κB are interrelated, since the former is
an NF-κB dependent gene [48]. Recent reports suggest
that the expression of A20 is influenced by, tumor de-
velopment, immune regulation and inflammation [48].
While A20-targeted therapies may certainly add to the
chemotherapeutic armamentarium, a better understand-
ing of A20 regulation and its molecular targets and
function is highly essential. Similarly, for personalized
Figure 5 Apoptosis studies: ι-car-γ- Fe2O3 nanocomposite led to apoptotic characteristics in HCT116 cells; (A) Control-Hoechst 33342
staining (10X), (B) Nanocomposite treated cells-Hoechst 33342 staining (10X), (C) Nanocomposite treated cells-7-AAD staining (10X),
(D) Control-AO/EB staining (20X) and (E) Nanocomposite treated cells- AO/EB staining (20X).
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ducers and inhibitors) for each tumor hold great promise
and could be a novel area for research.
Altogether, results confirm that the exposure of
HCT116 cells to ι-car-γ-Fe2O3 nanocomposite resulted in
apoptotic cell death, nuclear fragmentation, apoptosome
formation, and upregulation of Bcl-2, Bcl-xL and caspase-
3 and downregulation of XIAP. It could be speculated thatcell death in the nanocomposite treated cells could be due
to the mitochondrial ROS and activation of death receptor
signaling pathway.
Methods
Preparation of ι-car-γ-Fe2O3 nanocomposite
Maghemite nanoparticles were prepared as described by
Russo et al. [60]. These were synthesized by the reduction
Figure 6 Apoptosis studies: (A) Quantification of apoptosis by the annexin-V/PI double staining assay using flow cytometry; LL (low left),
LR (low right), UR (upper right), and UL (upper left) denote viable (live), early apoptotic, late apoptotic and necrotic cells, respectively.
(B) The cell cycle analysis performed by flow cytometry showing percentage of arrest in different phases of cell cycle (P3-G1, P4-G2/M, P5-S and
P6-G0 phases).
Raman et al. Journal of Nanobiotechnology  (2015) 13:18 Page 8 of 13of ferric chloride (FeCl3.6H2O) (37 mM) using ammoniacal
solution (3.5%) of sodium borohydride (NaBH4) (53 mM).
The mixture was heated at 100°C for 2 h and kept for
overnight aging at room temperature. The aged black
product was separated by neodymium magnets (N35,
263–287 KJ/m3BH, and 1170–1210 mJ flex density by
power magnet). The product was then washed several
times with milli-Q water and treated at 400°C for 2 h.Reddish brown particles obtained were dispersed in 3.5 l
of milli-Q by ultrasonication for 10 h. This gave a colloidal
nanoparticle suspension with good stability.
A known weight (7 mg) of ι-car was dissolved in 10 ml
of Milli-Q water at 40°C for 15 min, and 5 ml of γ-
Fe2O3 nanoparticle suspension (4 μg/ml) was added to
this drop by drop, under mild stirring. After uniform
dispersion by stirring and then sonication for 15 –
Figure 7 Real-time polymerase chain reaction: Activity of
X-linked inhibitor of apoptosis, A20, Bcl-2, Bcl-xL, caspase-3
and PARP-1were examined. The relative activities of A20, Bcl-2,
Bcl-xL and caspase3 in HCT116 cells treated with ι-car-γ- Fe2O3
nanocomposite for 24 h were higher than control cells. β-actin
was examined as an endogenous control. Significant difference is
observed between control and XIAP (p < 0.01), A20 (P < 0.05), Bcl-2
(p < 0.01), Bcl-xL (p < 0.01), caspase3 (p < 0.05) and PARP-1 (p < 0.01).
*- p < 0.05, **-p < 0.01.
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for further study.
Characterization of ι-car-γ-Fe2O3 nanocomposite
Size and surface charge of ι-car and ι-car-γ-Fe2O3 nano-
composite were estimated using Microtrac Particle
Analyzer (Zetatrac, India). Surface morphology of the ly-
ophilized products was analyzed using scanning electron
microscope (FEI Quanta FEG 200-High Resolution Scan-
ning Electron Microscope). UV spectra of ι-car and ι-car-γ-
Fe2O3 nanocomposites (1 mg/ ml) were obtained using
UV/Visible spectrometer (UV/Vis Spectrophotometer, V-
550, Jasco Corporation, India; Spectra Manager ver.1.53.01,
Jasco). FTIR spectra were recorded using a KBr pellet in
FTIR spectrometer (Perkin Elmer, USA). The percentage
transmittance (%T) was recorded in the spectral region of
400–4500 cm−1 with 20 scan per sample. Powder X-ray
diffraction patterns of ι-car and nanocomposite were re-
corded using CuK α radiation (λ = 0.1541 nm) with Bruker
D8 X-ray diffractometer.
Anticancer activity of ι-car-γ-Fe2O3 nanocomposite
Human embryonic kidney cell lines (HEK293) and rat
myoblast cell lines (L6) were maintained in DMEM and
human colon cancer cell line (HCT116) was maintained
in RPMI1640, containing 10% FBS and 5% antibiotic in a
humidified atmosphere of 5% CO2, at 37°C. The cytotoxicactivity of ι-car, γ-Fe2O3 and ι-car-γ-Fe2O3 nanocomposite
were evaluated against these cell lines using 3-[4, 5-
dimethythiazol-2-yl]-3, 5-diphenyltetrazolium bromide
dye (MTT) [40]. 1 × 105 cells/ ml were seeded in 700 μL
of media in the wells of a 24-well microplate and incu-
bated for 24 h. Various concentrations of ι-car (0, 100,
200, 400, 600, 800 and 1000 μg/ml), γ-Fe2O3 (0, 2.5, 5, 10,
30, 50 and 100 μg/ml) and ι-car-γ-Fe2O3 nanocomposite
(0, 25, 50, 100, 200, 400, 500 μg/ml in DMEM and RPMI
1640, respectively at a pH of 7.4) were added and incu-
bated for 24 h. 70 μl/ well (7.5 mg/ml) of MTT in phos-
phate buffer saline (PBS) is added to each well and again
incubated for 4 h. The medium was removed and 700 μl/
well of dimethyl sulfoxide (DMSO) was added to dissolve
the formazan. Cell viabilities were determined by mea-
suring the absorbance at 570 nm using a Microplate
reader (Enspire, Multimode plate reader, Perkin Elmer,
Singapore). Each experiment was repeated thrice. The cell
viability (%) was calculated according to the following
equation:
Cell viability %ð Þ ¼ OD570sample=OD570control
 
 100
Where, OD570sample and OD570control represent mea-
surements from the treated and untreated wells,
respectively.
Apoptosis studies
For analysing the morphological changes due to apop-
tosis, cells were seeded at 3 × 105 cells/ml into the wells
of a 6-well plate and cultured for 24 h. Then they were
treated with 500 μg/ml of ι-car-γ-Fe2O3 nanocomposite,
washed with PBS and stained with 10 μg/ml of Hoechst
33342 for 30 min at 37°C. The cells were observed using
an inverted fluorescent microscope (Leica Microsystems,
Germany). The cells were fixed with cold 2% of parafor-
maldehyde (PFA) for 20 min, washed with cold PBS and
stained with 7-aminoactinomycin (7-AAD) for 20 min.
They were then observed using an inverted fluorescent
microscope (Leica Microsystems, Germany) and photo-
graphed. To detect the nuclear damage or chromatin
condensation, treated and untreated cells (1 × 106 cells)
were harvested using trypsin, washed and mixed with
100 μl of PBS. 10 μl of cells were double-stained using
acridine orange (AO) and ethidium bromide (EB) (5 μl
of 50 μg/ml). They were then observed and photo-
graphed using an inverted fluorescent microscope (Leica
Microsystems, Germany). Acridine orange is taken up by
both viable and nonviable cells and they emit green
fluorescence if intercalated into double-stranded nucleic
acid (DNA) or red fluorescence if bound to single
stranded nucleic acid (RNA). Ethidium bromide is taken
up only by nonviable cells and so emits red fluorescence
Table 3 Primers for real-time PCR
Forward: Reverse:
β-actin 5′-CTCACCATGGATGATGATATCGC 5′-AGGAATCCTTCTGACCCATGC
XIAP 5′- GCGCGAAAAGGTGGACAAGT 5′- CTGCTCGTGCCAGTGTTGAT
A20 5′-AGTCTGCAGTCTTCGTGGC 5′-AGTCCTGGTCAAGGCAGGAG
Bcl-2 5′-TCCTGGCTGTCTCTGAAGACT 5′-AGCCTGCAGCTTTGTTTCAT
Bcl-xL 5′- ACTCTTCCGGGATGGGGTAA 5′- AATGAGGTGCAAAGTCCCCC
PARP-1 5′-CTACTCGGTCCAAGATCGCC 5′-TGAAAAAGCCCTAAAGGCTCA
Raman et al. Journal of Nanobiotechnology  (2015) 13:18 Page 10 of 13by intercalation into DNA. Based on the fluorescence
emission and the morphological aspect of chromatin
condensation in the stained nuclei, cells are classified as
viable cells (uniform bright green nuclei with an organized
structure), apoptotic cells (have intact membrane but have
started to undergo DNA cleavage, so have green nuclei
but perinuclear chromatin condensation is visible as
bright green patches or fragments), late apoptotic cells
(orange to red nuclei with condensed or fragmented chro-
matin) and necrotic cells (uniformly orange to red nuclei
with a condensed structure). The study was done in tripli-
cates. Percentage of apoptotic and necrotic cells were cal-
culated using the following formulae,
% Apoptotic cells ¼ VAþNVAð Þ=ðVNþ VA
þNVNþNVAÞ  100
% Necrotic cells ¼ NVNð Þ=VNþ VAþNVN
þNVA 100
Where,
VN = viable cells with normal nuclei (bright green
chromatin with organized structure),
VA = viable cells with apoptotic nuclei (bright green
chromatin which is highly condensed or fragmented)
NVN = nonviable cells with normal nuclei (bright
orange chromatin with organized structure),
NVA = nonviable cells with apoptotic nuclei (bright
orange chromatin which is highly condensed or
fragmented).
The morphology of apoptotic cells was determined
with the help of an annexin V-FITC and PI double-
staining technique [41]. HCT116 cells were seeded onto
6-well plates (5 × 103 cells/well) and cultured for 24 h.
After treatment with or without ι-car-γ-Fe2O3 for 24 h,
they were stained with the annexin V-FITC labeling
solution and 5 μl of PI (50 μg/ml). The plates were
incubated for 15 min in the dark, and then images of
the cells were acquired using BD FACSVerse™ flow
cytometer. The nucleus of the cells with apoptotic
morphology (condensation/fragmentation) or annexin
V-positive cells was analyzed using the BD FACSuite™
software (BD Biosciences, Germany). For each analysis,
3000 cells were recorded.
Distribution of the cells in various phases in the cycle
was determined using a flow cytometre [41]. After treat-
ment with or without ι-car-γ-Fe2O3, the cells were
harvested using trypsin, washed with cold PBS and incu-
bated with 10 μg/ml of RNase A for 30 min at room
temperature. PI (5 μl of 5 μg/ml) was added to the cell
suspension and they were incubated for 10 min in the
dark. The DNA content was analyzed by flow cytometre
(BD FACSVerse™ flow cytometer, BD FACSuite™ software,BD Biosciences, Germany). The proportion of cells in G1,
S and G2/ M phases were determined. 10000 cells were
recorded during each reading.
ROS plays a key role in the oxidative stress and its im-
balance causes cellular damage. To quantify ROS, cells
were incubated with ι-car-γ-Fe2O3 and labeled with 2 μl
of 20 mM stock solution of 2′, 7′-dichlorofluorescin
diacetate (DCFH-DA) at 37°C for 30 min. The cellular
fluorescence intensity was measured after washing the
cells with PBS at an excitation and emission wavelengths
of 485 and 530 nm, respectively, using a Microplate
reader (Enspire, Multimode plate reader, Perkin Elmer,
Singapore). DCFH-DA enters the cell where it reacts
with ROS to form the highly fluorescent dichlorofluores-
cein (DCF) [61].Real-time polymerase chain reaction
Cells were harvested after 24 h of treatment with PBS
and 500 μg/ml of ι-car-γ-Fe2O3. Total-RNA was ex-
tracted using the RNAiso Plus (Total RNA extraction re-
agent, Takara Bio Inc., Japan) [62]. The quality of RNA
was evaluated by measuring the absorbance (Nanodrop
2000 Spectrophotometer, Thermoscientific, USA) at 260
and 280 nm which indicates its concentration and pur-
ity. The High Capacity cDNA Reverse Transcription Kits
Protocol (Life Technologies, India) was used to prepare
the cDNA according to the manufacturer’s instructions.
All the samples were stored at −20°C. Quantitative PCR
was conducted in 20 μl reactions containing KAPA
SYBR® FAST qPCR kit (KAPA Biosystems, Wilmington,
Massachusetts) using the Mastercycler ep realplex4
PCR system (Eppendorf, Australia). The primers are
shown in Table 3. Reaction mixtures were incubated for
an initial denaturation at 95°C for 3 min followed by
40 cycles of 95°C for 3 sec, 56°C for 15 sec and 72°C for
15 sec. For each sample, the expression level of each
mRNA was quantified as the cycle threshold difference
(ΔΔCt) with respect to β-actin as internal housekeeping
gene. Real time PCR data were analyzed using the
2-ΔΔCt relative quantification method using the given
formulae. All the reactions were performed in triplicate.
Figure 8 Gel Formation: Gels from (A) ι-car with cations and
(B) ι-car with γ-Fe2O3.
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where
Ct (target, untreated) = Ct value of gene of interest in
untreated sample
Ct (ref, untreated) = Ct value of control gene in
untreated sample
Ct (target, treated) = Ct value of gene of interest in
treated sample
Ct (ref, treated) = Ct value of control gene in treated
sample
Western blot analysis
Untreated HCT 116 (control) and cells treated with
500 μg/ml of ι-car-γ-Fe2O3 nanocomposite for 24 h,
were lysed and whole cell lysates were extracted with
RIPA (Radio-Immunoprecipitation Assay) lysis buffer
and protein concentrations were measured using Nano-
drop 2000 Spectrophotometer (Thermoscientific, USA).
Samples containing equal concentrations of protein were
separated by 10% SDS-PAGE (Bio-Rad Mini Protean
Tetra Cell, India) and transferred to nitrocellulose mem-
branes and blot device (Kiran X-ray Cassette, Kiran
Medical Systems Ltd, India). The nitrocellulose sheet
was incubated for 1 h with 5% milk (v/v). Pre-stained
and un-stained broad range protein ladder (Puregene,
Genetix Biotech Asia Pvt. Ltd., India) was used to distin-
guish MW of PARP and its cleavage products, noting
that the MW of PARP was 116 kD, the apoptotic deg-
radation product was 89 kD, and the necrotic products
were 50 kD [54]. The membranes were blocked with 5%
skimmed milk in phosphate saline buffer with Tween for
1 h at room temperature and maintained overnight at 4°C
with PARP antibody (rabbit) prepared in skimmed milk
(Cell Signaling Technology Inc., India). Membranes were
then incubated with anti-rabbit horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling Technol-
ogy Inc., India) at room temperature for 1 h 30 min.
Antibody-bound proteins were detected using enhanced
chemiluminescence (ECL).
Statistical analysis
Groups of data were compared with Analysis of variance
(ANOVA) using SPSS software (Chicago, IL, USA). A
p value less than 0.05 was considered to be statistically
significant.
Conclusions
This novel, biocompatible and biodegradable hybrid
nano ι-CGN-γ-Fe2O3 composite has been successfully
prepared and characterized by various analytical tech-
niques such as UV-spectroscope, HR-SEM, DLS, FTIRand Powder XRD. The results confirm the integration of
maghemite nanoparticles to the sulphate groups of
carrageenan. They have properties that can make them
attractive and lucrative in biomedical applications. Tuning
the surface properties of this nanocomposite by changing
the concentration ratio of ι-car and γ-Fe2O3 can make
them more dynamic in targeting cancer cells. Initiating
the inhibition of growth in cancer cells without being
cytotoxic to normal cell lines makes it a promising nano-
vector in drug delivery. The nanocomposite induces alter-
ations in the cancer cells that are related to the apoptosis
process through ROS-mediated mitochondrial pathway,
by increasing ROS production and inducing mitochon-
drial oxidative damage, combined with upregulation of
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way. This is also accompanied by upregulation of Bcl-2
and Bcl-xL indicating the damage of mitochondrial wall
and probable production of pro-apoptotic proteins. Hence
the ι-car-γ-Fe2O3 nanocomposite has potential as an effi-
cient chemotherapeutic agent, since targeting of chemo-
therapeutic agents is related to its capacity to induce
apoptosis.
Our studies on gelation (data not shown, except Figure 8)
showed that ι-CGN with γ-Fe2O3 nanoparticles did not
require any addition of cations, as γ-Fe2O3 nanoparti-
cles themselves served as cations in neutralizing the
charges and in promoting gelation. Gel forming ability
of the nanocomposite can be exploited in targeted drug
delivery and cancer hyperthermia. Surface charge, gel
forming ability and the magnetic properties of our
ι-CGN-γ-Fe2O3 composite can be tuned to fit into ap-
propriate applications by changing the nanoparticle
concentration. Research to explore their significance in
chemotherapy, controlled drug delivery and hyperther-
mia are to be continued.
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